Study type: In vivo/preclinical · Status: Verified against declared source
Exposure to the antimicrobial chemical sequence LL-37 produces dendritic cells optimized for immunotherapy.
Oncoimmunology · 2019
Study scale: Dendritic cells (DCs) play a critical role in activating cytotoxic CD8+ T-cell responses against tumors (reviewed in1) and as a consequence there is significant interest in developing DC-based vaccines as personalized cancer therapies.1–3 This strategy has led to the approval of the immunostimulant Sipuleucel-T, a mixed preparation of myeloid cells treated to induce DC differentiation, for the treatment of hormone refractory metastatic prostate cancer.4 In general, clinical trials have proven DC-based therapies to be well tolerated, enabling patients to maintain quality of life;4,5 however, overall their clinical efficacy has been disappointing.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
A wider examination of surface markers showed that LL-37-DC displayed a range of characteristics of the naturally occurring subset of cDC1 cells, with a significantly greater proportion expressing CLEC9A, XCR1, CCR7, and TLR3 than in the control population, while significantly fewer LL-37-DC expressed PD-L1 and SIRP-α (Figure 2(h)).
Methods
Dendritic cells (DCs) play a critical role in activating cytotoxic CD8+ T-cell responses against tumors (reviewed in1) and as a consequence there is significant interest in developing DC-based vaccines as personalized cancer therapies.1–3 This strategy has led to the approval of the immunostimulant Sipuleucel-T, a mixed preparation of myeloid cells treated to induce DC differentiation, for the treatment of hormone refractory metastatic prostate cancer.4 In general, clinical trials have proven DC-based therapies to be well tolerated, enabling patients to maintain quality of life;4,5 however, overall their clinical efficacy has been disappointing.
Scale or participants
Dendritic cells (DCs) play a critical role in activating cytotoxic CD8+ T-cell responses against tumors (reviewed in1) and as a consequence there is significant interest in developing DC-based vaccines as personalized cancer therapies.1–3 This strategy has led to the approval of the immunostimulant Sipuleucel-T, a mixed preparation of myeloid cells treated to induce DC differentiation, for the treatment of hormone refractory metastatic prostate cancer.4 In general, clinical trials have proven DC-based therapies to be well tolerated, enabling patients to maintain quality of life;4,5 however, overall their clinical efficacy has been disappointing.
Key findings
Immunization of patients with autologous, ex vivo matured dendritic cell (DC) preparations, in order to prime antitumor T-cell responses, is the focus of intense research.
Limitations and uncertainty
Dendritic cells (DCs) play a critical role in activating cytotoxic CD8+ T-cell responses against tumors (reviewed in1) and as a consequence there is significant interest in developing DC-based vaccines as personalized cancer therapies.1–3 This strategy has led to the approval of the immunostimulant Sipuleucel-T, a mixed preparation of myeloid cells treated to induce DC differentiation, for the treatment of hormone refractory metastatic prostate cancer.4 In general, clinical trials have proven DC-based therapies to be well tolerated, enabling patients to maintain quality of life;4,5 however, overall their clinical efficacy has been disappointing.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.